Biorestorative Therapies Inc (BRTX) Stock Price, Quote & News

Company Profile

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral di...

Industry: Biotechnology

Sector: Healthcare

Phone: 631 760 8100

Website: www.biorestorative.com

Address:

40 Marcus Drive, Suite 1, Melville, United States

Dsradoff720 May. 13 at 9:26 AM

$CRML and $BRTX are my two stocks im all in on (10s of thousands. Not much to some but my life savings). Only a pectacular some even could say potentially world altering news from each. Yet they both are not doing very well. I’ve learned a lot in the few months about stocks since I’ve started investing which is probably worth more than I’ve lost in a non tangable perspective. $CRML is the future for the western world with mining rare earth elements at large scale. $BRTX is the future for fixing spine issues with stem cells to cure disc issues (im a spine injury patient) as well as long term space travel and they are preclinical on a crazy awesome alternative to ozempic using brown fat (kinda how bears hibernate and stay warm internally) injected once instead of glp1 (side effects with ongoing injections) with amazing phase 2 data and potentially accelerated approval path. Point being once/if I sell, these will go to the moon! Sorry for holding yall back by holding 😜! Just venting!😂

4 · Reply

Dsradoff720 May. 12 at 7:37 PM

$BRTX how does the FDA commissioner departure affect us?

0 · Reply

Usually_Im_Right May. 12 at 6:49 PM

$BRTX send it over a $1

0 · Reply

DT_2906 May. 8 at 11:02 AM

$BRTX on the move 🚀

1 · Reply

_Burn_ May. 7 at 7:41 PM

$BRTX https://x.com/BioRestorative/status/2052419347898044822?s=20 https://t.co/QrjEVVaN4a

0 · Reply

Dsradoff720 May. 7 at 5:32 PM

$BRTX they need to eye a partnership or this is going to be a RS situation.

0 · Reply

Dsradoff720 May. 7 at 4:10 PM

$BRTX let’s gooo! Great data!

0 · Reply

jpurr May. 7 at 4:04 PM

$BRTX If the new data was presented yesterday, why did they wait until now to press release?

0 · Reply

Scamstock May. 7 at 2:01 PM

$BRTX PT .35 IMO if it happens to hit .18 to .20 before the big pop to .35 then I will tripple my position otherwise just sitting where I am with my .232 average 🍺❄️ /filing play / very

0 · Reply

Dsradoff720 May. 6 at 4:38 PM

$BRTX 1pmcst is the second presentation.

0 · Reply

BioRestorative Therapies reports expanded Phase 2 blinded dataset for BRTX-100

May 7, 2026, 12:00 PM EDT - 5 days ago

BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease

Apr 30, 2026, 10:36 AM EDT - 12 days ago

BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform

2026-04-21T13:19:35.000Z - 21 days ago

BioRestorative Therapies announces partnership with David Goldberg, M.D.

Apr 21, 2026, 8:00 AM EDT - 21 days ago

BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform

2026-04-07T14:23:38.000Z - 5 weeks ago

BioRestorative Therapies announces strategic collaboration with 203 Creates

Apr 7, 2026, 8:15 AM EDT - 5 weeks ago

BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform

2026-04-02T12:00:42.000Z - 5 weeks ago

BioRestorative Therapies price target lowered to $15 from $18 at Roth Capital

2026-03-30T12:53:07.000Z - 6 weeks ago

BioRestorative Therapies reports blinded data from mesenchymal stem cells trial

Mar 30, 2026, 8:00 AM EDT - 6 weeks ago

BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

Mar 19, 2026, 8:00 AM EDT - 7 weeks ago

BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

Mar 5, 2026, 8:00 AM EST - 2 months ago

BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026

2026-03-04T13:33:10.000Z - 2 months ago

BioRestorative Therapies issues letter to shareholders

2026-02-24T13:45:03.000Z - 2 months ago

BioRestorative Therapies expands global protection for ThermoStem

Feb 24, 2026, 8:30 AM EST - 2 months ago

BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs

Feb 13, 2026, 8:30 PM EST - 3 months ago

BioRestorative Announces Closing of $5.0 Million Public Offering

2026-02-12T12:50:13.000Z - 3 months ago

BioRestorative Therapies prices $5.0M public offering of common stock at $0.35

Feb 11, 2026, 10:30 PM EST - 3 months ago

BioRestorative Announces Pricing of $5.0 Million Public Offering

2026-02-11T12:40:48.000Z - 3 months ago

BioRestorative Therapies expects to sumbit Phase 3 trial IND in 2H26

Feb 11, 2026, 7:30 AM EST - 3 months ago

BioRestorative Announces Positive Outcome from Type B Meeting with FDA

2026-02-10T13:11:31.000Z - 3 months ago

BioRestorative completes patient enrollment in Phase 2 trial of BTRX-100

2026-02-09T22:40:19.000Z - 3 months ago

BioRestorative Therapies files to sell 9.71M units

2025-11-18T21:50:10.000Z - 6 months ago

BioRestorative Therapies files to sell 508,592 shares of common stock for holder

2025-11-17T12:16:47.000Z - 6 months ago

BioRestorative Therapies granted Type B meeting on BRTX-100 BLA pathway

Nov 12, 2025, 4:30 PM EST - 6 months ago

BioRestorative Therapies Earnings Call Transcript: Q3 2025

Nov 5, 2025, 4:30 PM EST - 6 months ago

BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

2025-10-27T11:35:06.000Z - 7 months ago

BioRestorative awarded notice of allowance from JPO for ThermoStem platform

Oct 27, 2025, 7:30 AM EDT - 7 months ago

BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market

2025-10-22T13:40:37.000Z - 7 months ago

BioRestorative Therapies names Crystal Romano head, global commercial operations

Oct 22, 2025, 9:35 AM EDT - 7 months ago

BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio

Oct 15, 2025, 9:35 AM EDT - 7 months ago

BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit

Oct 7, 2025, 9:25 AM EDT - 7 months ago

BioRestorative CEO Lance Alstodt Interviewed on “The Big Biz Show”

2025-10-06T18:35:11.000Z - 7 months ago

BioRestorative Therapies announces $1.085M registered direct offering

Oct 6, 2025, 2:28 PM EDT - 7 months ago

BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market

Aug 12, 2025, 4:30 PM EDT - 9 months ago

BioRestorative Therapies Earnings Call Transcript: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 10 months ago

BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

Jun 18, 2025, 10:50 AM EDT - 11 months ago

BioRestorative Therapies Transcript: Status Update

Jun 18, 2025, 9:35 AM EDT - 11 months ago

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates

2025-06-17T13:30:34.000Z - 11 months ago

BioRestorative Therapies announces $2M share repurchase program

Jun 17, 2025, 9:25 AM EDT - 11 months ago

BioRestorative Announces Share Repurchase Program

2025-06-13T11:50:14.000Z - 11 months ago

BioRestorative Therapies reports preliminary data from Phase 2 trial of BRTX-100

Jun 13, 2025, 7:45 AM EDT - 11 months ago

BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease

2025-06-10T12:15:44.000Z - 1 year ago

BioRestorative Therapies appoints Sandy Lipkins for business development

Jun 9, 2025, 7:45 AM EDT - 1 year ago

BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

BioRestorative Therapies Earnings Call Transcript: Q1 2025

May 13, 2025, 9:15 AM EDT - 1 year ago

Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data

May 8, 2025, 4:30 PM EDT - 1 year ago

BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025

May 7, 2025, 9:15 AM EDT - 1 year ago

BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025

Apr 15, 2025, 8:30 AM EDT - 1 year ago

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities

Apr 10, 2025, 9:15 AM EDT - 1 year ago

BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States

Mar 27, 2025, 4:30 PM EDT - 1 year ago

BioRestorative Therapies Earnings Call Transcript: Q4 2024

Feb 27, 2025, 10:30 AM EST - 1 year ago

BioRestorative Therapies Transcript: Status Update

Feb 27, 2025, 9:45 AM EST - 1 year ago

BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain

Feb 26, 2025, 8:15 PM EST - 1 year ago

BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update

Feb 20, 2025, 8:30 AM EST - 1 year ago

BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program

Dec 5, 2024, 6:45 AM EST - 1 year ago

BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program

Nov 13, 2024, 4:30 PM EST - 1 year ago

BioRestorative Therapies Earnings Call Transcript: Q3 2024

Nov 5, 2024, 7:10 AM EST - 1 year ago

BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health

Oct 3, 2024, 4:15 PM EDT - 1 year ago

BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 19, 2024, 6:55 AM EDT - 1 year ago

BioRestorative Therapies' IFATS 2024 Presentation to Feature ThermoStem® Platform's Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs

Jul 23, 2024, 7:10 AM EDT - 1 year ago

BioRestorative Therapies' Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine

Jun 27, 2024, 7:40 AM EDT - 2 years ago

BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program

Jun 17, 2024, 7:05 AM EDT - 2 years ago

BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results

Jun 13, 2024, 7:00 AM EDT - 2 years ago

BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program

Jun 4, 2024, 8:50 AM EDT - 2 years ago

BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference

May 24, 2024, 7:45 PM EDT - 2 years ago

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice

May 15, 2024, 9:00 AM EDT - 2 years ago

BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market

May 14, 2024, 4:10 PM EDT - 2 years ago

BioRestorative Therapies Provides First Quarter 2024 Business Update

May 8, 2024, 7:30 AM EDT - 2 years ago

BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity

Apr 30, 2024, 4:15 PM EDT - 2 years ago

BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Apr 30, 2024, 7:30 AM EDT - 2 years ago

BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology

Apr 16, 2024, 7:45 AM EDT - 2 years ago

BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment

Apr 8, 2024, 7:45 AM EDT - 2 years ago

BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease

Apr 3, 2024, 4:38 PM EDT - 2 years ago

BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants

Apr 1, 2024, 7:45 AM EDT - 2 years ago

BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K

Mar 11, 2024, 4:15 PM EDT - 2 years ago

BioRestorative Therapies to Participate in the 36th Annual ROTH Conference

Dsradoff720 May. 13 at 9:26 AM

4 · Reply

Dsradoff720 May. 12 at 7:37 PM

$BRTX how does the FDA commissioner departure affect us?

0 · Reply

Usually_Im_Right May. 12 at 6:49 PM

$BRTX send it over a $1

0 · Reply

DT_2906 May. 8 at 11:02 AM

$BRTX on the move 🚀

1 · Reply

_Burn_ May. 7 at 7:41 PM

$BRTX https://x.com/BioRestorative/status/2052419347898044822?s=20 https://t.co/QrjEVVaN4a

0 · Reply

Dsradoff720 May. 7 at 5:32 PM

$BRTX they need to eye a partnership or this is going to be a RS situation.

0 · Reply

Dsradoff720 May. 7 at 4:10 PM

$BRTX let’s gooo! Great data!

0 · Reply

jpurr May. 7 at 4:04 PM

$BRTX If the new data was presented yesterday, why did they wait until now to press release?

0 · Reply

Scamstock May. 7 at 2:01 PM

$BRTX PT .35 IMO if it happens to hit .18 to .20 before the big pop to .35 then I will tripple my position otherwise just sitting where I am with my .232 average 🍺❄️ /filing play / very

0 · Reply

Dsradoff720 May. 6 at 4:38 PM

$BRTX 1pmcst is the second presentation.

0 · Reply

jpurr May. 6 at 2:42 PM

$BRTX Has closed below $1 for 60 days and counting. Did I miss them announcing they've received a Nasdaq Minimum Bid Price Notice?

2 · Reply

Dsradoff720 May. 6 at 12:39 PM

$BRTX it’s Gemini so may or may not be accurate

1 · Reply

DT_2906 May. 6 at 9:42 AM

will we see a press release from the new data presentations today for $BRTX ?

1 · Reply

dingsted May. 5 at 2:13 PM

$BRTX should see .35-.40 short term. They have alot going on

2 · Reply

Dsradoff720 May. 5 at 1:01 PM

$BRTX

1 · Reply

luminouslumens May. 4 at 7:17 PM

$BRTX 🤔

0 · Reply

Scamstock May. 4 at 4:51 PM

$BRTX .35

0 · Reply

RichardCraniumWozEre May. 4 at 3:14 PM

$BRTX Loooooong

0 · Reply

jpurr May. 2 at 3:53 PM

$BRTX

0 · Reply

jpurr May. 2 at 3:51 PM

$BRTX Good gracious! Now I see where a lot of the cash has gone... The stock went down 22% in 2025 and has dropped 80% more so far in 2026. Yet these guys gave themselves big cash bonuses for last year. CEO - $300,000 (on top of $596,666 cash salary), VP R&D - $287,500 (also on top of $566,666 cash salary), CFO - $140,000 (on top of a slightly more reasonable $343,750 cash salary). Add all the cash comp to option awards, the 3 top execs got paid $5.5 million, which is just shy of BRTX's $5.9 million entire rket cap! https://www.sec.gov/Archives/edgar/data/1505497/000102177126000068/brtx-20260501.htm

3 · Reply

GreggTwits May. 2 at 11:13 AM

$BRTX yes

0 · Reply

Market Cap	5.13M
Revenue (ttm)	360,000.00
Net Income (ttm)	-14.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,955.56%
Debt to Equity Ratio	0.00

Volume	575,000
Avg Vol	5,421,106
Day's Range	N/A - N/A
Shares Out	25.48M
Stochastic %K	7%
Beta	0.29
Analysts	Strong Sell
Price Target	$8.00